Float Short %

6.76

Margin Of Safety %

-16

Put/Call OI Ratio

0.42

EPS Next Q Diff

-0.2

EPS Last/This Y

0.46

EPS This/Next Y

-0.83

Price

29.47

Target Price

33.83

Analyst Recom

Performance Q

4.91

Relative Volume

0.66

Beta

0.48

Ticker: ALKS

20 items of 1

Date	Symbol	Last	P/C OI	P/C Vol	Total OI
2024-12-19	ALKS	29.97	0.31	8.00	4040
2024-12-20	ALKS	29.75	0.32	0.00	4054
2024-12-23	ALKS	29.49	0.29	6.07	3543
2024-12-24	ALKS	29.65	0.32	0.33	3641
2024-12-26	ALKS	29.72	0.32	30.00	3640
2024-12-27	ALKS	29.56	0.39	3.71	3857
2024-12-30	ALKS	28.78	0.43	12.56	3988
2024-12-31	ALKS	28.76	0.52	0.57	4281
2025-01-02	ALKS	28.76	0.52	2.94	4287
2025-01-03	ALKS	29.04	0.55	0.00	4425
2025-01-06	ALKS	28.47	0.50	0.26	4734
2025-01-07	ALKS	28.52	0.45	0.00	5689
2025-01-08	ALKS	28.4	0.45	0.00	5700
2025-01-09	ALKS	28.42	0.45	0.00	5700
2025-01-10	ALKS	28.04	0.44	0.29	5801
2025-01-13	ALKS	28.33	0.44	0.03	5817
2025-01-14	ALKS	28.5	0.43	1.40	5922
2025-01-15	ALKS	29.05	0.43	0.00	5930
2025-01-16	ALKS	29.75	0.43	55.00	5964
2025-01-17	ALKS	29.48	0.42	0.10	5943
Date	Symbol	Last	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2024-12-19	ALKS	29.97	239.0	-178.0	2.60
2024-12-20	ALKS	29.73	239.0	-178.8	2.60
2024-12-23	ALKS	29.50	239.0	-178.6	2.60
2024-12-24	ALKS	29.65	239.0	-176.1	2.60
2024-12-26	ALKS	29.81	239.0	-176.1	2.60
2024-12-27	ALKS	29.54	239.0	-179.0	2.60
2024-12-30	ALKS	28.78	239.0	-182.4	2.60
2024-12-31	ALKS	28.75	239.0	-177.4	2.60
2025-01-02	ALKS	28.77	239.0	-177.1	2.60
2025-01-03	ALKS	29.04	239.0	-175.1	2.60
2025-01-06	ALKS	28.49	239.0	-181.0	2.60
2025-01-07	ALKS	28.53	239.0	-176.7	2.60
2025-01-08	ALKS	28.42	239.0	-178.0	2.60
2025-01-09	ALKS	28.42	239.0	-177.1	2.60
2025-01-10	ALKS	28.07	239.0	-179.6	2.60
2025-01-13	ALKS	28.35	239.0	-175.2	2.60
2025-01-14	ALKS	28.50	239.0	-176.0	2.60
2025-01-15	ALKS	29.04	239.0	-173.3	2.60
2025-01-16	ALKS	29.75	239.0	-172.3	2.60
2025-01-17	ALKS	29.47	239.0	-179.1	2.60
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2024-12-19	ALKS	-5.11	-0.56	8.63
2024-12-20	ALKS	-5.11	-0.56	8.63
2024-12-23	ALKS	-5.15	-0.61	8.63
2024-12-24	ALKS	-5.15	-0.61	8.63
2024-12-26	ALKS	-5.09	-0.61	7.87
2024-12-27	ALKS	-5.11	-0.61	7.87
2024-12-30	ALKS	-5.15	-0.69	7.87
2024-12-31	ALKS	-5.15	-0.69	7.87
2025-01-02	ALKS	-5.11	-0.69	7.87
2025-01-03	ALKS	-5.11	-0.69	7.87
2025-01-06	ALKS	-5.06	0.12	7.87
2025-01-07	ALKS	-5.06	0.12	7.87
2025-01-08	ALKS	-5.11	0.12	7.87
2025-01-09	ALKS	-5.11	0.12	7.87
2025-01-10	ALKS	-5.11	0.12	7.87
2025-01-13	ALKS	-5.11	0.10	6.76
2025-01-14	ALKS	-5.11	0.10	6.76
2025-01-15	ALKS	-5.11	0.10	6.76
2025-01-16	ALKS	-5.11	0.10	6.76
2025-01-17	ALKS	-5.11	0.10	6.76
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

0.61

Avg. EPS Est. Current Quarter

0.75

Avg. EPS Est. Next Quarter

0.41

Insider Transactions

-5.11

Institutional Transactions

0.1

Beta

0.48

Average Sales Estimate Current Quarter

380

Average Sales Estimate Next Quarter

325

Fair Value

24.63

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

10.4

Max Drawdown 5-Year %

-38.5

Target Price

33.83

P/E

15.01

Forward P/E

16.67

PEG

1.12

P/S

3.17

P/B

3.69

P/Free Cash Flow

15.13

EPS

1.96

Average EPS Est. Cur. Y

2.6

EPS Next Y. (Est.)

1.77

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

22.15

Relative Volume

0.66

Return on Equity vs Sector %

6.7

Return on Equity vs Industry %

17.2

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.01

EBIT Estimation

-179.1

Alkermes plc

Sector: Healthcare

Industry: Drug Manufacturers - Specialty & Generic

Employees: 2100

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

stock quote shares ALKS – Alkermes plc Stock Price stock today

news today ALKS – Alkermes plc stock forecast ,stock prediction 2023 2024 2025

marketwatch ALKS – Alkermes plc yahoo finance google finance

stock history ALKS – Alkermes plc invest stock market

stock prices ALKS premarket after hours

ticker ALKS fair value insiders trading

Investment involves risk. As a general rule, you should only trade in financial products that you are familiar with and understand the risk associated with them. The risk warning described in each financial product below is not exhaustive, you should carefully consider your investment experience, financial situation, investment objective, risk tolerance level and consult your independent financial adviser as to the suitability of your situation prior making any investment.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: ALKS

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Get Started

About

Last Quarter Act. EPS

Average EPS Est. Cur. Y